Migration, Adaptation, and What the Rise of Chinese Biotechs Means for U.S. Clinical Trials
Biotech’s center of gravity isn’t fixed to any one zip code.
Financing and regulatory momentum in the United States is stumbling, there’s no question about it. As the chaos continues, biotechnological and medical innovation is increasingly being accelerated and created in countries outside the US. Now, we aren’t here to write a eulogy for American science; on the contrary, as scientists, it’s our responsibility to make practical observations from the trenches of study start-up. Patients can’t wait for industry trends to steady. They need predictable timelines, capable partners, and routes that actually move.
The funding environment has shifted materially. In 2025, total biopharma financing declined from approximately $102 billion to $82 billion, a ~20% drop year-over-year, driven by reduced follow-on financings and a constrained IPO market. IPO proceeds fell to roughly $1.6 billion for the year, marking the lowest levels in over a decade and reinforcing a continued investor shift toward later-stage, de-risked assets.
At the same time, China’s biotech ecosystem continues to gain momentum. Chinese biopharma out-licensing reached approximately $137 billion in 2025, with deal volume and cross-border partnerships accelerating as global pharma increasingly sources innovation from China.
Meanwhile, operational predictability has become a rare commodity. Leadership churn and staffing constraints at the FDA have nudged some sponsors to price in delays, and to scope early-phase work in jurisdictions where timelines feel more reliable. Quietly, sponsors are mapping first-in-human or proof-of-concept runs in Europe and Australia, then looping back to the U.S. once the data mature. None of this is ideological; it’s timeline math with lives attached.
The Rise of Chinese Biotechs: A Case Study in Steady Momentum
Enter China.
Over the last few years, China’s regulatory environment has moved toward faster, clearer pathways for innovative drugs, with proposals now on the table to halve the clinical trial review clock for novel medicines from 60 to 30 working days. That shift sits atop a broader reform arc aligning with GCP/ICH standards and expanding priority review mechanisms. While they seem minor, all of these small, technical moves add up to real cycle-time advantages for certain programs.
The output is visible in both regulatory velocity and global deal activity, with China continuing to increase novel drug approvals and expand its presence in global licensing transactions. Chinese regulators have proposed cutting IND review waits to ~30 working days. Licensing activity has followed suit as Western pharmas and investors increasingly source assets and data packages from Chinese biotechs. On the execution side, a mature homegrown CRO layer has scaled capabilities while growing North America backlogs, making them increasingly attractive for sponsors facing aggressive first-patient-in timelines.
That said, speed on paper doesn’t always translate to speed in practice. Sponsors working with CROs that lack a meaningful U.S. presence can face significant execution challenges, particularly in early-phase trials, where site selection, investigator relationships, and patient access are critical. Platform-driven site identification can look efficient upfront, but often misses the nuance of site-level performance, competing studies, and true enrollment (and, sometimes, provide inaccurate information). In our experience, timelines are ultimately determined less by regulatory clocks and more by the strength of relationships and operational visibility on the ground.
If you’re in the U.S. like us, this can feel uncomfortable. We get it. But discomfort isn’t a strategy. The actionable takeaway is simple: innovation has diversified. Some of it will still start here in the U.S.; much of it will start everywhere. In practice, that means more sponsors are hedging risk with parallel or staged geographies for Phase 1/2, pre-clinical and FIH, then consolidating to the U.S. for later phases and commercialization. It also means international CROs — whether they be Chinese, European, Australian, or something else entirely — are no longer alternatives but integral parts of a resilient, global clinical research operating model.
If the first half of this year taught us anything, it’s that capital and confidence can zag. Patients can’t. As different regions accelerate approvals, streamline reviews, and scale experienced CRO capacity, it’s worth considering whether it’s reasonable — responsible, even — to place early bets where the path is smoother, then bring mature packages to the U.S. with stronger data and tighter timelines.
We can also see the sentiment shift beyond clinical trials. Commentators tracking deal flow, IPO droughts, and leadership signals have highlighted the same pattern: the U.S. deal engine is uneven, China’s engines are humming, and sponsors are responding with portfolio triage and geographic creativity. None of this implies absolutist mindsets. It simply reflects a rebalancing that smart teams can use to protect their programs, and their patients, from preventable drift.
So what’s WINNIEDEL’s position? Pragmatic, patient-first, and very much hands-on. We believe in:
Global by default. Our start-up playbooks are built for multi-country options from day one. That includes site-readiness checks and KOL relationships across continents with trusted partners in other regions as programs warrant.
Boots on the ground. Clinical trials are complex, adaptive human systems. Spreadsheets don’t open sites. People do. Our model leverages long-term person-to-person relationships with experts who know the needs, investigators, and patient communities of each site — and can therefore anticipate friction before it turns into delay.
Cost discipline without corner-cutting. In a funding environment that rewards thrift, we meet or come under sponsor budgets while protecting scientific rigor and inspection readiness. The point is to de-risk, not de-scope. And, at WINNIEDEL ONCOLOGY we don’t believe in change orders.
WINNIEDEL’s view is not that one country is “winning” and another is “losing.” Our view is that patients win when we adapt. The rise of Chinese biotechs is one part of a larger shift toward a genuinely global innovation map.
Patients ALWAYS Come First. The rest is just routing.
Get in touch with us today to learn more about how WINNIEDEL can help you adapt to global industry shifts.